Intercept Pharma (ICPT) Misses Q4 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Issues 2019 Financial Guidance and Provides Business Update
February 28, 2019 7:15 AM ESTPositive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH studyÂ
Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full year 2018, consistent with previously issued guidanceÂ
Strong year-end cash position of approximately $436.2 millionÂ
2019 worldwide Ocaliva net sales projected between $225 million and $240 million and 2019 non-GAAP adjusted operating expenses projected between $450 million and $470 millionÂ
... More